Smoking and polymorphisms of fucosyltransferase gene Le affect success of H. pylori eradication with lansoprazole, amoxicillin, and clarithromycin

Epidemiology and Infection

Volumn 130, Issue 2, 2003, Pages 227-233

  Matsuo, K ^a,d   Hamajima, N ^a   Ikehara, Y ^e   Suzuki, T ^b   Nakamura, T ^b   Matsuura, A ^b   Tajima, K ^a   Tominaga, S ^c  

^a Division of Epidemiology   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADHESIN; AMOXICILLIN; CLARITHROMYCIN; FUCOSYLTRANSFERASE; LANSOPRAZOLE;

ADULT; AGED; ALLELE; ANTIGEN EXPRESSION; ARTICLE; CANCER CENTER; CLINICAL PRACTICE; CONFIDENCE INTERVAL; CONTROLLED STUDY; ERADICATION THERAPY; FEMALE; GENETIC POLYMORPHISM; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PROSPECTIVE STUDY; SMOKING; SMOKING CESSATION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; AMOXICILLIN; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; FEMALE; FUCOSYLTRANSFERASES; GENOTYPE; HELICOBACTER PYLORI; HUMANS; LEWIS BLOOD-GROUP SYSTEM; MALE; MIDDLE AGED; OMEPRAZOLE; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; SMOKING;

EID: 0037398365     PISSN: 09502688     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0950268802008129     Document Type: Article

References (44)

1. Anonymous. Infection with Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum, vol. 61. 1994: 177-240.
2. Peek RM, Jr., Blaser MJ. Pathophysiology of Helicobacter pylori-induced gastritis and peptic ulcer disease. Am J Med 1997; 102: 200-7.
3. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991; 338: 1175-6.
4. Ikehara Y, Nishihara S, Yasutomi H, et al. Polymorphisms of two fucosyltransferase genes (Lewis and Secretor genes) involving type I Lewis antigens are associated with the presence of anti-Helicobacter pylori IgG antibody. Cancer Epidemiol Biomarkers Prev 2001; 10: 971-7.
5. Nishihara S, Narimatsu H, Iwasaki H, et al. Molecular genetic analysis of the human Lewis histo-blood group system. J Biol Chem 1994; 269: 29271-8.
6. Kudo T, Iwasaki H, Nishihara S, et al. Molecular genetic analysis of the human Lewis histo-blood group system. II. Secretor gene inactivation by a novel single missense mutation A385T in Japanese nonsecretor individuals. J Biol Chem 1996; 271: 9830-7.
7. Narimatsu H, Iwasaki H, Nishihara S, et al. Genetic evidence for the Lewis enzyme, which synthesizes type-1 Lewis antigens in colon tissue, and intracellular localization of the enzyme. Cancer Res 1996; 56: 330-8.
8. Koda Y, Soejima M, Liu Y, Kimura H. Molecular basis for secretor type alpha(1,2)-fucosyltransferase gene deficiency in a Japanese population: a fusion gene generated by unequal crossover responsible for the enzyme deficiency. Am J Hum Genet 1996; 59: 343-50.
9. Boren T, Falk P, Roth KA, Larson G, Normark S. Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens. Science 1993; 262: 1892-5.
10. Ilver D, Arnqvist A, Ogren J, et al. Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging. Science 1998; 279: 373-7.
11. Hamajima N, Matsuo K, Saito T, et al. Interleukin 1 polymorphisms, lifestyle factors, and Helicobacter pylori infection. Jpn J Cancer Res 2001: 92: 383-9.
12. Hamajima N, Matsuo K, Suzuki T, et al. Low expression myeloperoxidase genotype negatively associated with Helicobacter pylori infection. Jpn J Cancer Res 2001; 92: 488-93.
13. El-Omar EM. The importance of interleukin 1 beta in Helicobacter pylori associated disease. Gut 2001; 48: 743-7.
14. Piedrafita FJ, Molander RB, Vansant G, Orlova EA, Pfahl M, Reynolds WF. An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem 1996; 271: 14412-20.
15. Montecucco C, Rappuoli R. Living dangerously: bow Helicobacter pylori survives in the human stomach. Nat Rev Mol Cell Biol 2001; 2: 457-66.
16. Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, Ishizaki T. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from an Oriental population. J Pharmacol Exp Ther 1992; 262: 1195-202.
17. Furuta T, Ohashi K, Kamata T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998; 129: 1027-30.
18. Tanigawara Y, Aoyama N, Kita T, et al. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Clin Pharmacol Ther 1999; 66: 528-34.
19. Labenz J, Stolte M, Blum AL, et al. Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin. Gut 1995; 37: 39-43.
20. Bertoni G, Sassatelli R, Nigrisoli E, et al. Triple therapy with azithromycin, omeprazole, and amoxicillin is highly effective in the eradication of Helicobacter pylori: a controlled trial versus omeprazole plus amoxicillin. Am J Gastroenterol 1996; 91: 258-63.
21. Goddard AF, Spiller RC. Helicobacter pylori eradication in clinical practice: one-week low-dose triple therapy is preferable to classical bismuth based triple therapy. Aliment Pharmacol Ther 1996; 10: 1009-13.
22. Moayyedi P, Chalmers DM, Axon AT. Patient factors that predict failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori. J Gastroenterol 1997; 32: 24-7.
23. Kamada T, Haruma K, Komoto K, et al. Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxicillin, and clarithromycin. Helicobacter 1999; 4: 204-10.
24. Maconi G, Parente F, Russo A, Vago L, Imbesi V, Porro GB. Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy? Am J Gastroenterol 2001; 96: 359-66.
25. Perri F, Villani MR, Festa V, Quitadamo M, Andriulli A. Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'. Aliment Pharmacol Ther 2001; 15: 1023-9.
26. Cutler AF, Schubert TT. Patient factors affecting Helicobacter pylori eradication with triple therapy. Am J Gastroenterol 1993; 88: 505-9.
27. Moshkowitz M, Konikoff FM, Peled Y, et al. One week triple therapy with omeprazole, clarithromycin and tinidazole for Helicobacter pylori: differing efficacy in previously treated and untreated patients. Aliment Pharmacol Ther 1996; 10: 1015-9.
28. Hamajima N, Matsuo K, Watanabe Y, et al. A pilot study to evaluate stomach cancer risk reduction by Helicobacter pylori eradication. Am J Gastroenterol 2002; 97: 764-5.
29. Marchildon P, Balaban DH, Sue M, et al. Usefulness of serological IgG antibody determinations for confirming eradication of Helicobacter pylori infection. Am J Gastroenterol 1999; 94: 2105-8.
30. Narimatsu H, Iwasaki H, Nakayama F, et al. Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients. Cancer Res 1998; 58: 512-8.
31. Hamajima N, Saito T, Matsuo K, Kozaki K, Takahashi T, Tajima K. Polymerase chain reaction with confronting two-pair primers for polymorphism genotyping. Jpn J Cancer Res 2000; 91: 865-8.
32. Matsuo K, Hamajima N, Suzuki R, et al. No substantial difference in genotype frequencies of interleukin and myeloperoxidase polymorphisms between malignant lymphoma patients and non-cancer controls. Haematologica 2001; 86: 602-8.
33. Danis VA, Millington M, Hyland VJ, Grennan D. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol 1995; 99: 303-10.
34. London SJ, Lehman TA, Taylor JA. Myeloperoxidase genetic polymorphism and lung cancer risk. Cancer Res 1997; 57: 5001-3.
35. Murray LJ, McCrum EE, Evans AE, Bamford KB. Epidemiology of Helicobacter pylori infection among 4742 randomly selected subjects from Northern Ireland. Int J Epidemiol 1997; 26: 880-7.
36. Woodward M, Morrison C, McColl K. An investigation into factors associated with Helicobacter pylori infection. J Clin Epidemiol 2000; 53: 175-81.
37. Hamajima N, Inoue M, Tajima K, et al. Lifestyle and anti-Helicobacter pylori immunoglobulin G antibody among outpatients. Jpn J Cancer Res 1997; 88: 1038-43.
38. Fontham ET, Ruiz B, Perez A, Hunter F, Correa P. Determinants of Helicobacter pylori infection and chronic gastritis. Am J Gastroenterol 1995; 90: 1094-101.
39. Rouquier S, Lowe JB, Kelly RJ, Fertitta AL, Lennon GG, Giorgi D. Molecular cloning of a human genomic region containing the H blood group alpha(1,2)fucosyltransferase gene and two H locus-related DNA restriction fragments. Isolation of a candidate for the human Secretor blood group locus. J Biol Chem 1995; 270: 4632-9.
40. Kelly RJ, Rouquier S, Giorgi D, Lennon GG, Lowe JB. Sequence and expression of a candidate for the human Secretor blood group alpha(1,2)fucosyltransferase gene (FUT2). Homozygosity for an enzyme-inactivating nonsense mutation commonly correlates with the nonsecretor phenotype. J Biol Chem 1995; 270: 4640-9.
41. Kukowska-Latallo JF, Larsen RD, Nair RP, Lowe JB. A cloned human cDNA determines expression of a mouse stage-specific embryonic antigen and the Lewis blood group alpha(1,3/1,4)fucosyltransferase. Genes Dev 1990; 4: 1288-303.
42. Mollicone R, Reguigne I, Kelly RJ, et al. Molecular basis for Lewis alpha(1,3/1,4)-fucosyltransferase gene deficiency (FUT3) found in Lewis-negative Indonesian pedigrees. J Biol Chem 1994; 269: 20987-94.
43. Gerhard M, Lehn N, Neumayer N, et al. Clinical relevance of the Helicobacter pylori gene for blood-group antigen-binding adhesin. Proc Natl Acad Sci USA 1999; 96: 12778-83.
44. Cutler AF, Prasad VM. Long-term follow-up of Helicobacter pylori serology after successful eradication. Am J Gastroenterol 1996; 91: 85-8.